Welcome
Support Centre
09 February 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
PROmotion of Breastfeeding Intervention Trial
ISRCTN ISRCTN37687716
ClinicalTrials.gov identifier
Public title PROmotion of Breastfeeding Intervention Trial
Scientific title Breastfeeding duration and exclusivity: impact on child health and development
Acronym PROBIT
Serial number at source MOP-53155
Study hypothesis Amended as of 11/03/2009:
Experimental intervention will lead to increased exclusivity and duration of breastfeeding, and hence to improved infant and child health.

Initial information at time of registration:
Experimental intervention will lead to increased exclusivity and duration of breastfeeding, and hence to reduced infection and eczema in infancy.

As of 25/03/2009 this record has been updated to include an updated anticipated end date; the initial end date at the time of registration was 31/03/2008.
Ethics approval Research Ethics Board of McGill University Health Centre approved on the 28th November 2001
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Healthy, full-term, breastfed infants
Participants - inclusion criteria 1. Birth weight equal and above 2500 g, either sex
2. Gestational age equal and above 37 weeks
3. Maternal intention to breastfeed
Participants - exclusion criteria 1. Neonatal disease or condition contraindicating breastfeeding
2. Neonatal disease or condition making breastfeeding difficult or impossible
3. Maternal psychosis
4. Maternal human immunodeficiency virus (HIV) or active tuberculosis (TB)
5. Maternal chemotherapy or radioisotopes
Anticipated start date 01/04/2002
Anticipated end date 01/12/2011
Status of trial Ongoing
Patient information material
Target number of participants 17046
Interventions Experimental group: breastfeeding promotion intervention at maternity hospitals and affiliated polyclinics
Control group: continuation of maternity hospital and polyclinic practices existing at time of
randomisation
Primary outcome measure(s) One or more episodes of gastrointestinal infection in first 12 months of life.
Secondary outcome measure(s) Amended as of 11/03/2009:
8. Anthropometry, lipoproteins, glucose, insulin, adiponectin, and IGF at age 11 years

Initial information at time of registration:
1. Respiratory infections in first 12 months
2. Atopic eczema in first 12 months
3. Weight, length, and head circumference at 1, 2, 3, 6, 9, and 12 months
4. Blood pressure (BP) at age 6.5 and 9 years
5. Asthma, hay fever, atopic eczema, and allergy skin tests at age 6.5 years
6. Intelligence quotient (IQ) and behaviour at age 6.5 years
7. Oral/dental health at age 6.5 years
8. Lipids, lipoproteins, glucose, insulin, and HbA1c at age 9 years
Sources of funding 1. Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MOP-53155)
2. United Nations Children's Fund (UNICEF)
3. Thrasher Research Fund (USA)
4. National Health Research and Development Program (NHRDP) - Health Canada (Canada)

Added as of 11/03/2009:
5. European Union (EU)
6. National Institutes of Health (NIH) (USA)
Trial website http://www.epi.bris.ac.uk/probit3/PROBIT%20III.htm
Publications Results in:
1. http://www.ncbi.nlm.nih.gov/pubmed/17855282
2. http://www.ncbi.nlm.nih.gov/pubmed/18065591
3. http://www.ncbi.nlm.nih.gov/pubmed/18310164
4. http://www.ncbi.nlm.nih.gov/pubmed/18458209
Contact name Dr  Michael S.  Kramer
  Address The Montreal Children's Hospital
2300 Tupper Street, T-118
  City/town Montreal
  Zip/Postcode H3H 1P3
  Country Canada
  Tel +1 514 4124400 ext. 22687
  Fax +1 514 4124253
  Email michael.kramer@mcgill.ca
Sponsor McGill University (Canada)
  Address 845 Sherbrooke Street West
James Administration Bldg., Suite 429
  City/town Montreal
  Zip/Postcode H3A 2T5
  Country Canada
  Sponsor website: http://www.mcgill.ca/
Date applied 25/02/2005
Last edited 25/03/2009
Date ISRCTN assigned 09/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central